RT Journal Article
T1 Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort.
A1 Lujan-Barroso, Leila
A1 Botteri, Edoardo
A1 Caini, Saverio
A1 Ljungberg, Börje
A1 Roswall, Nina
A1 Tjønneland, Anne
A1 Bueno-de-Mesquita, Bas
A1 Gram, Inger T
A1 Tumino, Rosario
A1 Kiemeney, Lambertus A
A1 Liedberg, Fredrik
A1 Stocks, Tanja
A1 Gunter, Marc J
A1 Murphy, Neil
A1 Cervenka, Iris
A1 Fournier, Agnes
A1 Kvaskoff, Marina
A1 Häggström, Christel
A1 Overvad, Kim
A1 Lund, Eiliv
A1 Waaseth, Marit
A1 Fortner, Renee Turzanski
A1 Kühn, Tilman
A1 Menendez, Virginia
A1 Sanchez-Perez, Maria-Jose
A1 Santiuste, Carmen
A1 Perez-Cornago, Aurora
A1 Zamora-Ros, Raul
A1 Cross, Amanda J
A1 Trichopoulou, Antonia
A1 Karakatsani, Anna
A1 Peppa, Eleni
A1 Palli, Domenico
A1 Krogh, Vittorio
A1 Sciannameo, Veronica
A1 Mattiello, Amalia
A1 Panico, Salvatore
A1 van Gils, Carla H
A1 Onland-Moret, N Charlotte
A1 Barricarte, Aurelio
A1 Amiano, Pilar
A1 Khaw, Kay-Tee
A1 Boeing, Heiner
A1 Weiderpass, Elisabete
A1 Duell, Eric J
K1 Adolescent
K1 Hormone Replacement Therapy
K1 Pregnancy
K1 Risk Factors
AB Urothelial carcinoma is the predominant (95%) bladder cancer subtype in industrialized nations. Animal and epidemiologic human studies suggest that hormonal factors may influence urothelial carcinoma risk. We used an analytic cohort of 333,919 women from the European Prospective Investigation into Cancer and Nutrition Cohort. Associations between hormonal factors and incident urothelial carcinoma (overall and by tumor grade, tumor aggressiveness, and non-muscle-invasive urothelial carcinoma) risk were evaluated using Cox proportional hazards models. During a mean of 15 years of follow-up, 529 women developed urothelial carcinoma. In a model including number of full-term pregnancies (FTP), menopausal status, and menopausal hormone therapy (MHT), number of FTP was inversely associated with urothelial carcinoma risk (HR≥5vs1 = 0.48; 0.25-0.90; Ptrend in parous women = 0.010) and MHT use (compared with nonuse) was positively associated with urothelial carcinoma risk (HR = 1.27; 1.03-1.57), but no dose response by years of MHT use was observed. No modification of HRs by smoking status was observed. Finally, sensitivity analyses in never smokers showed similar HR patterns for the number of FTP, while no association between MHT use and urothelial carcinoma risk was observed. Association between MHT use and urothelial carcinoma risk remained significant only in current smokers. No heterogeneity of the risk estimations in the final model was observed by tumor aggressiveness or by tumor grade. A positive association between MTH use and non-muscle-invasive urothelial carcinoma risk was observed. Our results support that increasing the number of FTP may reduce urothelial carcinoma risk. More detailed studies on parity are needed to understand the possible effects of perinatal hormone changes in urothelial cells.
PB American Association for Cancer Research
YR 2020
FD 2020-05-19
LK http://hdl.handle.net/10668/15655
UL http://hdl.handle.net/10668/15655
LA en
NO Lujan-Barroso L, Botteri E, Caini S, Ljungberg B, Roswall N, Tjønneland A, et al. Menstrual Factors, Reproductive History, Hormone Use, and Urothelial Carcinoma Risk: A Prospective Study in the EPIC Cohort. Cancer Epidemiol Biomarkers Prev. 2020 Aug;29(8):1654-1664.
DS RISalud
RD Jul 29, 2025